Imbruvica

Imbruvica uses and dosage

Imbruvica (Ibrutinib), is a prescription medicine used to treat certain cancers such as Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma, Marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia, Chronic graft-versus-host (cGVHD) disease. Imbruvica manufactured by Janssen-Cilag Pharma Ltd. in USA. Ibrutinib has to take orally once daily with a glass of water.

Imbruvica side effects

The most common adverse reactions of Ibrutinib are: Thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, skin rash, abdominal pain, vomiting, and loss of appetite.

Originator brand

Imbruvica by Pharmacyclics

Made by

Janssen-Cilag Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.